Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 2660       
ORIGINAL ARTICLE
Year : 2013  |  Volume : 138  |  Issue : 6  |  Page : 882-887

Effect of zoledronic acid on bone mineral density in patients of celiac disease: A prospective, randomized, pilot study


1 Department of Endocrinology, Postgraduate Institute of Medical Education & Research, Chandigarh, India
2 Department of Histopathology, Postgraduate Institute of Medical Education & Research, Chandigarh, India
3 Department of Gastroenterology, Postgraduate Institute of Medical Education & Research, Chandigarh, India

Correspondence Address:
Sanjay Kumar Bhadada
Associate Professor, Department of Endocrinology, Postgraduate Institute of Medical Education & Research, Chandigarh 160 012
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 24521630

Rights and PermissionsRights and Permissions

Background & objectives: The symptoms of celiac disease (CD) are varied and metabolic bone disease (MBD) is less recognized amongst all manifestations in CD patients. Bone disease in CD is attributed to secondary hyperparathyroidism, which in turn is associated with increased bone remodelling. Improvement in bone mineral density (BMD) with gluten free diet (GFD) is known, but the data on efficacy of bisphosphonates in CD patients are limited. Bisphosphonates being a potent inhibitor of bone resorption may be useful in patients with CD having low BMD. The aim of the present investigation was to study the effect of zoledronic acid on BMD in CD patients. Methods: A total of 28 CD patients were randomized to receive GFD, calcium and cholecalciferol (group A), and zoledronic acid (group B). Baseline biochemical tests and T-score by dual energy x-ray absorptiometer were done and repeated after 12 months. Results: The T-score showed improvement in the control arm (group A) from -3.31 ± 1.46 to -2.12 ± 1.44, a gain of 35.9 per cent (P<0.05) and in drug arm (group B) -2.82 ± 1.27 to -1.06 ± 1.84, registering a gain of 62.4 per cent (P<0.001). However, there was no difference in improvement of T-score in zoledronic acid group as compared to the control group. Interpretation & conclusions: Administration of zoledronic acid was not found to be better than GFD alone in increasing BMD in CD patients with low BMD in this pilot study.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed739    
    Printed21    
    Emailed0    
    PDF Downloaded307    
    Comments [Add]    

Recommend this journal